FDA Approves Brixadi

FDA Approves Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder Plymouth Meeting, Pa. — May 23, 2023—Braeburn announces that the U.S.…